Entrar/Registro  
INICIO ENGLISH
 
Medicina Crítica
   
MENÚ

Contenido por año, Vol. y Num.

Índice de este artículo

Información General

Instrucciones para Autores

Mensajes al Editor

Directorio






>Revistas >Medicina Crítica >Año 2003, No. 5


Carrillo ER, Carvajal RR, Hernández AC
Vasopresina: una nueva alternativa terapéutica en el enfermo grave
Rev Asoc Mex Med Crit y Ter Int 2003; 17 (5)

Idioma: Español
Referencias bibliográficas: 74
Paginas: 162-171
Archivo PDF: 121.76 Kb.


Texto completo




RESUMEN

En los últimos años se han descrito una serie de alteraciones endocrinológicas asociadas a deterioro hemodinámico y vasodilatación refractaria en el estado de choque y paro cardiaco, una de las cuales por su relevancia es la deficiencia de vasopresina. La vasopresina actúa a través de 3 diferentes receptores de proteína G denominados V1a, V1b y V2. En diversos estudios experimentales y ensayos clínicos se ha demostrado su utilidad en choque séptico, choque post-cardiotomía, choque hipovolémico en fase dilatada, intoxicaciones y en paro cardiaco secundario a taquicardia ventricular sin pulsos y fibrilación ventricular.
En estados de choque con vasodilatación la dosis recomendada es de 0.01 a 0.04 UI/min, dosis más elevadas se asocian a isquemia miocárdica, esplácnica y cutánea. En taquicardia ventricular sin pulsos y fibrilación ventricular de acuerdo a la Asociación Americana de Cardiología es recomendación IIb y se utiliza a dosis única de 40 UI.


Palabras clave: Vasopresina, vasodilatación, choque, paro cardiaco, fibrilación ventricular, taquicardia ventricular.


REFERENCIAS

  1. Barberis C, Mouillac B, Durroux T. Structural bases of vasopressin/oxytocin receptor function. J Endocrinol 1998; 156:223-229.

  2. Bourque CW. Osmorregulation of vasopressin neurons: a synergy of intrinsic and synaptic processes. Prog Brain Res 1998;119:59-76.

  3. Leng G, Brown CH, Russell JA. Physiological pathways regulating the activity of magnocellular neurosecretory cells. Prog Neurobiol 1999;57:625-655.

  4. Sklar AH, Schrier RW. Central nervous system mediators of vasopressin release. Physiol Rev 1983;63:1243-1280.

  5. Bourque CW, Oliet SH, Richard D. Osmoreceptors, osmoreception, and osmoregulation. Front Neuroendocrinol 1994;15:231-274.

  6. Robertson GL, Shelton RL, Athar S. The osmoregulation of vasopressin. Kidney Int 1976;10:25-37.

  7. Schrier RW, Berl T, Anderson RJ. Osmotic and nonosmotic control of vasopressin release. Am J Physiol 1979;236: 321-332.

  8. Reid IA. Role of nitric oxide in the regulation of renin and vasopressin secretion. Front Neuroendocrinol 1994;15: 351-383.

  9. Day TA, Randle JC, Renaud LP. Opposing α-and β-adrenergic mechanisms mediate dose-dependent actions of norepinephrine on supraoptic vasopressin neurones in vivo. Brain Res 1985;358:171-179.

  10. Morton JJ, Padfield PL, Forsling ML. A radioimmunoassay for plasma arginine-vasopressin in man and dog: application to physiological and pathological states. J Endocrinol 1975; 65: 411-424.

  11. Czaczkes JW. Physiologic studies of antidiuretic hormone by its direct measurement in human plasma. J Clin Invest 1964;43:1625-1640.

  12. Share L, Kimura T, Matsui K et al. Metabolism of vasopressin. Fed Proc 1985;44:59-61.

  13. Chen P. Vasopressin: New uses in critical care. Am J Med Sci 2002;324:146-154.

  14. Chen JM, Cullinane S, Spanier TB et al. Vasopressin deficiency and pressor hypersensitivity in hemodinamically unstable organ donors. Circulation 1999;100:244-246.

  15. Cowley AW Jr, Switzer SJ, Guinn MM. Evidence and quantification of the vasopressin arterial pressure control system in the dog. Circ Res 1980;46:58-67.

  16. Landry D, Oliver J. The pathogenesis of vasodilatory shock. N Engl J Med 2001;345:588-595.

  17. Surks HK, Mochisuki N, Kasai Y et al. Regulation of myosin phosphatase by a specific interaction with cGMP-dependent protein kinase Iα. Science 1999;286:1583-1587.

  18. Jackson WF. Ion channels and vascular tone. Hypertension 2000;35:173-178.

  19. Quayle JM, Nelson MT, Standen NB. ATP-sensitive and inwardly rectifying potassium channels in smooth muscle. Physiol Rev 1997;77:1165-1232.

  20. Titheradge MA. Nitric oxide in septic shock. Biochim Biophys Acta 1999;1411:437-455.

  21. Taylor BS, Geller DA. Molecular regulation of the human inducible nitric oxide synthase (iNOS) gene. Shock 2000;13:413-424.

  22. Kilbourn R. Nitric oxide synthase inhibitors –a mechanism-based treatment of septic shock. Crit Care Med 1999;27:857-858.

  23. Errington ML, Rocha e Silva M Jr. Vasopressin clearance and secretion during haemorrhage in normal dogs and in dogs with experimental diabetes insipidus. J Physiol 1972;227:395-418.

  24. Sharshar T, Blanchard A, Paillard M, Raphael JC, Gajdos P, Annane D. Circulating vasopressin levels in septic shock. Crit Care Med 2003;31:1752-1758.

  25. Sharshar T, Carlier R, Blanchard A, Feydy A, Gray F, Paillard M, Raphael JC, Gajdos P, Annane D. Crit Care Med 2002;30:497-500.

  26. Landry DW, Levin HR, Gallant EM et al. Vasopressin pressor hypersensitivity in vasodilatory septic shock. Crit Care Med 1997;25:1279-1282.

  27. Buijk SE, Bruining HA. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation 1998; 98:187.

  28. Landry DW, Levin HR, Gallant EM et al. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation 1997;95:1122-1125.

  29. Malay MB, Ashton RC, Landry DW et al. Low dose vasopressin in the treatment of vasodilatory septic shock. J Trauma 1999;47:699-703.

  30. Argenziano M, Choudhri AF, Oz MC et al. Prospective randomized trial of arginine vasopressin in the treatment of vasodilatory shock after left ventricular assist device placement. Circulation 1997;96:286-290.

  31. Argenziano M, Chen JM, Choudhri AF et al. Management of vasodilatory shock after cardiac surgery: identification of predisponing factors and use of a novel pressor agent. Thorac Cardiovasc Surg 1998;116:973-980.

  32. Argenziano M, Chen JM, Cullinane S et al. Arginine vasopressin in the management of vasodilatory hypotension after cardiac transplantation. J Heart Lung Transplant 1999;18:814-817.

  33. Rosenzweig EB, Starc TJ, Chen JM et al. Intravenous arginine-vasopressin in children with vasodilatory shock after cardiac surgery. Circulation 1999;100:182-186.

  34. Morales D, Madigan J, Cullinane S et al. Reversal by vasopressin of intractable hypotension in the late phase of hemorrhagic shock. Circulation 1999;100:226-229.

  35. Morales D, Cullinane S, Spainer TB et al. Arginine vasopressin in the treatment of 50 patients with postcardiotomy vasodilatory shock. Ann Thorac Surg 2000;69: 102-106.

  36. Chen JM, Cullinane S, Spainer TB et al. Vasopressin deficiency and pressor hypersensitivity in hemodynamically unestable organ donors. Circulation 1999;100:244-246.

  37. Gold JA, Cullinane S, Chen JM. Vasopressin as an alternative to norephinphrine in the treatment of milrinona induced hypotension. Crit Care Med 2000;28:249-252.

  38. Tsuneyoshi I, Yamada H, Kakihana Y et al. Hemodynamic and metabolic effects of low dose vasopressin in vasodilatory septic shock. Crit Care Med 2001;29:350-360.

  39. Carrillo ER, González SJ. Vasopresina para el manejo del choque refractario con vasodilatación. Rev Asoc Med Crit y Ter Int 2003;17:5-18.

  40. Carrillo ER, Calvo CB. Vasopresina para el tratamiento del choque refractario con vasodilatación en quemaduras graves. Cir Ciruj 2003;71:129-136.

  41. O’Brien A, Clapp L, Singer M. Terlipressin for norephinephrine-resistant septic shock. Lancet 2002;359:1209-1210.

  42. Meersschaert K. Terlipressin-ephedrine versus ephedrine to treat hypotension at the induction of anesthesia in patients chronically treated with angiotensina converting-enzyme inhibitors: a prospective, randomized, double-blinded, crossover study. Anesth Analg 2002;94:835-840.

  43. Voelckel WG, Raedler C, Wenzel V et al. Arginine vasopressin, but not epinephrine, improves survival in uncontrolled hemorrhagic shock after liver trauma in pigs. Critical Care Med 2003;31:1160-1165.

  44. Voelckel WG, Lurie KG, Lindner KH et al. Vasopressin improves survival after cardiac arrest in hypovolemic shock. Anesth Analg 2000;91:627-634.

  45. Kern KB, Niemann JT. Coronary perfusion pressure during cardiopulmonary resuscitation. In: Paradis NA, Halpernin HR, Nowak RM, editors. Cardiac arrest: the science and practice of resuscitation medicine. Baltimore: Williams & Wilkins; 1996:270-285.

  46. Wenzel V, Ewy GA, Lindner KH. Vasopressin and endothelin during cardiopulmonary resuscitation. Crit Care Med 2000;28:233-235.

  47. Ditchey RV, Lindenfeld JA. Failure of epinephrine to improve the balance between myocardial oxygen supply and demand during CPR in dogs. Circulation 1988;78: 382-389.

  48. Niemann JT, Haynes KS, Garner D et al. Postcountershock pulseless rythms: response to CPR, artificial cardiac pacing, and adrenergic agonists. Ann Emerg Med 1986; 15:112-120.

  49. Tang W, Weil MH, Gazmuri R et al. Pulmonary ventilation/perfusion defects induced by epinephrine during CPR. Circulation 1991;84:2101-2107.

  50. Thrush DN, Downs JB, Smith RA. Is epinephrine contraindicated during cardiopulmonary resuscitation? Circulation 1997;96:2709-2714.

  51. Tang W, Weil MH, Sun S et al. Epinephrine increases the severity of postresuscitation myocardial dysfunction. Circulation 1995;92:3089-3093.

  52. Tovar OH, Jones JL. Epinephrine facilitates cardiac fibrillation by shortening action potential refractoriness. J Mol Cell Cardiol 1997;29:1447-1455.

  53. Woodhouse SP, Cox S, Boyd P et al. High dose and standard dose adrenaline do not alter survival, compared with placebo, in cardiac arrest. Resuscitation 1995;30: 243-249.

  54. Schultz CH, Rivers EP, Feldkamp CS et al. A characterization of hypothalamic-pituitary-adrenal axis function during and after human cardiac arrest. Crit Care Med 1993;21:1339-1347.

  55. Kornberger E, Prengel AW, Krismer A et al. Vasopressinmediated adrenocorticotropin release increases plasma cortisol concentrations during cardiopulmonary resuscitation. Crit Care Med 2000;28:3517-3521.

  56. Lindner KH, Haak T, Keller A et al. Release of endogenous vasopressors during and after cardiopulmonary resuscitation. Heart 1996;75:145-150.

  57. Lindner KH, Prengel AW, Plenninger EG et al. Vasopressin improves vital organ blood flow during closed-chest cardiopulmonary resuscitation in pigs. Circulation 1995; 91:215-221.

  58. Wenzel V, Lindner KH, Augenstein S et al. Vasopressin combined with epinephrine decreases cerebral perfusion compared with vasopressin alone during cardiopulmonary resuscitation in pigs. Stroke 1998;29:1467-1468.

  59. Wenzel V, Lindner KH, Prengel AW et al. Endobronchial vasopressin improves survival during CPR in pigs. Anesthesiology 1997;86:1375-1381.

  60. Ralston SH, Tacker WA, Showen L et al. Endotracheal versus intravenous epinephrine during electromechanical dissociation with CPR in dogs. Ann Emerg Med 1985;14: 1044-1048.

  61. Wenzel V, Lindner KH, Augenstein S et al. Intraosseous vasopressin improves coronary perfusion pressure rapidly during cardiopulmonary resuscitation in pigs. Crit Care Med 1999;27:1565-1569.

  62. Wenzel V, Lindner KH, Krismer AC et al. Repeated administration of vasopressin, but not epinephrine, maintains coronary perfusion pressure after early and late administration during prolonged cardiopulmonary resuscitation in pigs. Circulation 1999;99:1379-1384.

  63. Prengel AW, Lindner KH, Keller A. Cardiovascular function during the postresuscitation phase after cardiac arrest in pigs: a comparison of epinephrine versus vasopressin. Crit Care Med 1996;24:2014-2019.

  64. Prengel AW, Lindner KH, Wenzel V et al. Splachnic and renal blood flow after CPR with epinephrine and vasopressin in pigs. Resuscitation 1998;38:19-24.

  65. Wenzel V, Lindner KH, Krismer AC et al. Improved survival and neurological outcome with vasopressin after prolonged resuscitation in pigs. J Am Coll Cardiol 2000;35: 527-533.

  66. Kampfi A, Schmutzhard E, Franz G et al. Prediction of recovery from post-traumatic vegetative state with cerebral magnetic resonance imaging. Lancet 1998;351:1763- 1767.

  67. Voelckel WG, Lurie KG, Lindner KH et al. Comparison of epinephrine and vasopressin in a pediatric porcine model of asphyxial cardiac arrest. Crit Care Med 2000;28:3777- 3783.

  68. Lindner KH, Dirks B, Strohmenger HU et al. A randomized comparison of epinephrine and vasopressin in patients without-of-hospital ventricular fibrillation. Lancet 1997; 349:535-537.

  69. Stiell IG, Hebert P, Wells G et al. Evaluation of the myocardial ischemia subgroup in the vasopressin epinephrine cardiac arrest (VECA) trial. Acad Emerg Med 2000;7:439- 041.

  70. Krismer AC, Wenzel V, Lindner KH et al. Vasopressin oder adrenalin beider Therapie des präklinischen Herskreislaufstillstandes: Studienprotokoll einer vergleichenden, multizentrischen, europäischen, blockrandomisierten DoppelblindStudie unter der Schirmherrschaft des European Resuscitation Council. Noftall Rettungsmed 1999;2: 478-485.

  71. Stiell IG, Hebert PC, Wells GA et al. Vasopressin versus epinephrine for in-hospital cardiac arrest: A randomized controlled trial. Lancet 2001;358:105-109.

  72. Lurie KG, Voelckel WG, Iskos DN et al. Combination drug therapy with vasopressin, adrenaline (epinephrine) and nitroglycerin improves vital organ blood in a porcine model of ventricular fibrillation. Resuscitation 2002;54:187-194.

  73. Mann K, Berg RA, Nadkarni V. Beneficial effects of vasopressin in prolonged pediatric cardiac arrest: a case series. Resuscitation 2002;52:149-156.

  74. Dellinger P. Cardiovascular management of septic shock. Crit Care Med 2003;31:946-955.



>Revistas >Medicina Crítica >Año2003, No. 5
 

· Indice de Publicaciones 
· ligas de Interes 






       
Derechos Resevados 2019